| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7630745 | Journal of Pharmaceutical and Biomedical Analysis | 2014 | 7 Pages |
Abstract
- GDC-0980 (Apitolisib) is a small molecule dual PI3K/mTor inhibitor.
- A SLE-LC-MS/MS analytical method was developed and validated for GDC-0980 in human plasma.
- Validation met criteria of the “Guidance for Industry” set by the FDA.
- Pharmacokinetic results of a phase I clinical trial are presented.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Analytical Chemistry
Authors
X. Ding, F. Li, J. McKnight, C. Schmidt, K. Strooisma, H. Shimizu, K. Faber, J.A. Ware, B. Dean,